ChiCTR2500108441 版本V1.0 版本创建时间2025/08/29 17:41:21 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500108441 

最近更新日期:

Date of Last Refreshed on:

2025-08-29 17:41:16 

注册时间:

Date of Registration:

2025-08-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

干细胞及干细胞外泌体对创面愈合的临床研究

Public title:

Clinical Study on the Application of Stem Cells and Stem Cell-Derived Exosomes in Wound Healing

注册题目简写:

English Acronym:

研究课题的正式科学名称:

干细胞及干细胞外泌体对创面愈合的临床研究

Scientific title:

Clinical Study on the Application of Stem Cells and Stem Cell-Derived Exosomes in Wound Healing

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王金涛 

研究负责人:

蔡宏 

Applicant:

Wang Jintao 

Study leader:

Cai Hong 

申请注册联系人电话:

Applicant telephone:

+86 10 6848 9948

研究负责人电话:

Study leader's
telephone:

+86 10 6848 9948

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangjt2188@163.com

研究负责人电子邮件:

Study leader's E-mail:

ch1031@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区阜成路30号

研究负责人通讯地址:

北京市海淀区阜成路30号

Applicant address:

No. 30, Fucheng Road, Haidian District, Beijing

Study leader's address:

No. 30, Fucheng Road, Haidian District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

10042

研究负责人邮政编码:

Study leader's postcode:

10042

申请人所在单位:

空军特色医学中心

Applicant's institution:

Air Force Medical Center

研究负责人所在单位:

空军特色医学中心

Affiliation of the Leader:

Air Force Medical Center

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

空特(科研)第2023-84-YJ01;空特(科研)第2023-84-YJ02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军空军特色医学中心伦理委员会

Name of the ethic committee:

Committee of Medical Ethics, Air Force Medical Center

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-20 00:00:00

伦理委员会联系人:

王威

Contact Name of the ethic committee:

Wang Wei

伦理委员会联系地址:

北京市海淀区阜成路30号

Contact Address of the ethic committee:

No. 30, Fucheng Road, Haidian District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6692 8575

伦理委员会联系人邮箱:

Contact email of the ethic committee:

kjtsll@126.com

研究实施负责(组长)单位:

空军特色医学中心

Primary sponsor:

Air Force Medical Center

研究实施负责(组长)单位地址:

北京市海淀区阜成路30号

Primary sponsor's address:

No. 30, Fucheng Road, Haidian District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

海淀区

Country:

China

Province:

Beijing

City:

Haidian

单位(医院):

空军特色医学中心

具体地址:

北京市海淀区阜成路30号

Institution
hospital:

Air Force Medical Center

Address:

No. 30, Fucheng Road, Haidian District, Beijing

经费或物资来源:

军委后勤重点开放项目

Source(s) of funding:

Military Commission Logistics Priority Opening Project

研究疾病:

二氧化碳点阵激光治疗面部凹陷性瘢痕所形成的急性创面  

Target disease:

Acute wounds formed by carbon dioxide fractional laser treatment of facial atrophic scars

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价人脐带间充质干细胞及其来源外泌体局部涂抹治疗急性创面的安全性和有效性;设置对照组(水凝胶),验证干细胞及来其源外泌体局部涂抹治疗急性创面的有效性非劣于对照组;通过临床及实验室检测指标和随访观察指标评价干细胞及来其源外泌体局部涂抹治疗急性创面的差异性。  

Objectives of Study:

To evaluate the safety and efficacy of topical application of human umbilical cord mesenchymal stem cells (hUC-MSCs) and their derived exosomes in the treatment of acute wounds. A control group (hydrogel) was established to demonstrate that the therapeutic efficacy of topical MSC and exosome treatment for acute wounds is non-inferior to the control intervention. The differential effects of topical MSC and exosome therapy on acute wound healing were assessed through clinical and laboratory parameters, as well as follow-up observational indicators.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.患者年龄18岁到60岁之间; 2.二氧化碳点阵激光治疗引起的急性创面,包括但不限于皮肤磨削治疗后的皮肤创面,面积>=3*3cm^2; 3.女性未处于妊娠期、哺乳期; 4.经化验检查未患乙肝、丙肝、艾滋病、梅毒等血液传染病; 5.未经过系统药物治疗或距上次药物治疗3个月以上时间; 6.同意签署知情同意书、愿意配合并同意入选条件患者。

Inclusion criteria

1. Patients aged between 18 and 60 years; 2. Acute wounds caused by carbon dioxide fractional laser treatment, including but not limited to skin wounds after skin abrasion treatment, with an area of >=3*3cm^2; 3. The female is not pregnant or lactating; 4. No hepatitis B, hepatitis C, AIDS, syphilis and other blood infectious diseases after laboratory examination; 5. Not undergoing systematic drug treatment or more than 3 months since the last drug treatment; 6. Patients who agree to sign the informed consent form, are willing to cooperate and agree to be selected.

排除标准:

1.瘢痕疙瘩病史; 2. 创面巨大或损毁严重; 3.有其他系统严重疾患; 4.妊娠期、哺乳期女性; 5.经化验检查患乙肝、丙肝、艾滋病、梅毒等血液传染病; 6.近期经过系统药物、封闭、激光等治疗。

Exclusion criteria:

1. History of keloids; 2. The wound is huge or severely damaged; 3. Have other serious systemic diseases; 4. Pregnant and lactating women; 5. Blood infectious diseases such as hepatitis B, hepatitis C, AIDS, syphilis and other blood infectious diseases after laboratory examination; 6. Recent treatment with systematic drugs, occlusion, laser, etc.

研究实施时间:

Study execute time:

From 2025-07-01 00:00:00 To 2026-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-08-30 00:00:00 To 2025-10-31 00:00:00

干预措施:

Interventions:

组别:

常规治疗组

样本量:

12

Group:

Conventional drug therapy group

Sample size:

干预措施:

取等体积水凝胶均匀涂抹于面部创伤处,室温避光保持安静30min。用药时程7天,每天给药1次,共计7次。

干预措施代码:

Intervention:

Apply equal volume hydrogel evenly to the facial wound and keep quiet at room temperature and away from light for 30 minutes. The medication schedule is 7 days, administered once a day, a total of 7 times.

Intervention code:

组别:

人脐带间充干细胞组

样本量:

12

Group:

hUC-MSC group

Sample size:

干预措施:

取1ml 浓度约为( 5~7)X10^7/ml 干细胞混悬液恒温水箱复温至37℃,于自制水凝胶内1:2混合,均匀涂抹于面部创伤处,室温避光保持静置30min。用药时程:7天,每天给药1次,共计7次

干预措施代码:

Intervention:

Take 1ml of stem cell suspension at a constant temperature water tank of about (5~7)X10^7/ml to reheat to 37°C, mix 1:2 in homemade hydrogel, apply evenly to the facial wound, and leave at room temperature away from light for 30 minutes. Medication schedule: 7 days, administered once a day, a total of 7 times

Intervention code:

组别:

人脐带间充干细胞外泌体组

样本量:

12

Group:

hUC-MSC-Exos group

Sample size:

干预措施:

取1ml 浓度约为 1mg/ml 外泌体溶液,于于自制水凝胶内1:2混合,均匀涂抹于面部创伤处,室温避光保持静置30min。用药时程:7天,每天给药1次,共计7次

干预措施代码:

Intervention:

Take 1ml of exosome solution at a concentration of about 1mg/ml, mix it 1:2 in a homemade hydrogel, apply it evenly to the wound area of the face, and leave it at room temperature for 30 minutes away from light. Medication schedule: 7 days, administered once a day, a total of 7 times

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

海淀区 

Country:

China

Province:

Beijing

City:

Haidian

单位(医院):

空军特色医学中心 

单位级别:

三甲 

Institution
hospital:

Air Force Medical Center

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

创面愈合率

指标类型:

主要指标

Outcome:

Wound healing rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

创面愈合时间

指标类型:

主要指标

Outcome:

Wound healing time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

是否出现并发症:感染、不愈合、瘢痕等

指标类型:

次要指标

Outcome:

Whether complications occur: infection, non-healing, scarring, etc

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤标志物

指标类型:

副作用指标

Outcome:

Tumor markers

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生皮肤与周围皮 肤的一致性(表面张力、颜色、有无凹陷和突出)

指标类型:

次要指标

Outcome:

Consistency of the newborn skin with the surrounding skin (surface tension, color, presence or absence of depressions and protrusions)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

局部微生物菌群

组织:

Sample Name:

Skin microbiome

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由试验数据管理员采用软件法随机生成随机数表。

Randomization Procedure (please state who generates the random number sequence and by what method):

Data administrator uses statistical software to randomly generate a random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用病例记录表(CRF)结合电子数据管理系统进行研究数据采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This study uses CRF and electronic data management system to collect and manage research data.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-08-29 17:41:16